NIOX Group PLC
82C
Company Profile
Business description
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Contact
Edmund Halley Road
Hayakawa Building
The Oxford Science Park
OxfordOX4 4GB
GBRT: +44 3303309356
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
92
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,694.60 | 61.20 | 0.71% |
| CAC 40 | 7,906.40 | 51.48 | 0.66% |
| DAX 40 | 21,505.70 | 77.46 | 0.36% |
| Dow JONES (US) | 44,556.04 | 134.13 | 0.30% |
| FTSE 100 | 8,570.77 | 12.79 | -0.15% |
| HKSE | 20,659.34 | 130.62 | -0.63% |
| NASDAQ | 19,654.02 | 262.06 | 1.35% |
| Nikkei 225 | 38,746.44 | 51.93 | -0.13% |
| NZX 50 Index | 12,828.55 | 76.49 | -0.59% |
| S&P 500 | 6,037.88 | 43.31 | 0.72% |
| S&P/ASX 200 | 8,427.00 | 53.00 | 0.63% |
| SSE Composite Index | 3,238.85 | 11.75 | -0.36% |